Detail akcie UCB SA online

Business Summary: Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, UCB SA revenues increased 26% to EUR7.74B. Net income increased 46% to EUR1.56B. Revenues reflect Bimzelx segment increase from EUR607M to EUR2.23B, Zilbrysq segment increase from EUR72M to EUR217M, USA segment increase of 52% to EUR4.61B, Unallocated segment increase from EUR19M to EUR94M. Net income benefited from Collaboration agreement EVENITY increase of 31% to EUR632M (income).